These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24419174)

  • 1. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.
    Shimizu K; Kotera Y; Aruga A; Takeshita N; Katagiri S; Ariizumi S; Takahashi Y; Yoshitoshi K; Takasaki K; Yamamoto M
    Hum Vaccin Immunother; 2014; 10(4):970-6. PubMed ID: 24419174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.
    Shimizu K; Kotera Y; Aruga A; Takeshita N; Takasaki K; Yamamoto M
    J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):171-8. PubMed ID: 21874278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor vaccine against recurrence of hepatocellular carcinoma.
    Peng BG; Liang LJ; He Q; Kuang M; Lia JM; Lu MD; Huang JF
    World J Gastroenterol; 2005 Feb; 11(5):700-4. PubMed ID: 15655825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma].
    Gao J; Chen M; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial.
    Matsui HM; Hazama S; Nakajima M; Xu M; Matsukuma S; Tokumitsu Y; Shindo Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Yoshino S; Ueno T; Oka M; Nagano H
    Cancer Immunol Immunother; 2021 Apr; 70(4):945-957. PubMed ID: 33074442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.
    Wang J; He XD; Yao N; Liang WJ; Zhang YC
    Can J Gastroenterol; 2013 Jun; 27(6):351-63. PubMed ID: 23781519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
    Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
    Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
    Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
    BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
    Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
    Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
    El Ansary M; Mogawer S; Elhamid SA; Alwakil S; Aboelkasem F; Sabaawy HE; Abdelhalim O
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):39-48. PubMed ID: 22886490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-based vaccine targeting aspartate-β-hydroxylas represents a promising therapeutic strategy for HCC.
    Zhou Y; Li C; Shi G; Xu X; Luo X; Zhang Y; Fu J; Chen L; Zeng A
    Immunotherapy; 2019 Nov; 11(16):1399-1407. PubMed ID: 31608722
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
    Lee JH; Lee Y; Lee M; Heo MK; Song JS; Kim KH; Lee H; Yi NJ; Lee KW; Suh KS; Bae YS; Kim YJ
    Br J Cancer; 2015 Dec; 113(12):1666-76. PubMed ID: 26657650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis.
    Chen C; Ma YH; Zhang YT; Zhang F; Zhou N; Wang X; Liu T; Li YM
    Cytotherapy; 2018 Aug; 20(8):975-989. PubMed ID: 30072299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
    Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of autologous tumor vaccine in preventing recurrence of hepatocellular carcinoma].
    Peng BG; Liang LJ; He Q; Zhou F; Lai JM; Lü MD; Huang JF
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):772-5. PubMed ID: 16248952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
    Takayama T; Sekine T; Makuuchi M; Yamasaki S; Kosuge T; Yamamoto J; Shimada K; Sakamoto M; Hirohashi S; Ohashi Y; Kakizoe T
    Lancet; 2000 Sep; 356(9232):802-7. PubMed ID: 11022927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.
    Barth RJ; Fisher DA; Wallace PK; Channon JY; Noelle RJ; Gui J; Ernstoff MS
    Clin Cancer Res; 2010 Nov; 16(22):5548-56. PubMed ID: 20884622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.